Navigation Links
Boehringer Ingelheim Expands Investigation of Interferon-free Hepatitis C Treatment Regimens to Reach More Patient Types through Presidio Pharmaceuticals Clinical Collaboration
Date:9/10/2013

p>Boehringer Ingelheim has a comprehensive interferon-free clinical trial program, HCVerso®, which includes three pivotal Phase 3 studies. The HCVerso® studies aim to enroll approximately 1,100 treatment-naive and experienced HCV genotype-1b (GT-1b) patients, including those who are interferon eligible or ineligible, and those with compensated liver cirrhosis.

For more information regarding the trial, please visit www.clinicaltrials.gov.

About Boehringer Ingelheim in Hepatitis C Virus (HCV)
In partnership with the scientific community, our clinical trial program is rigorously designed to find answers to the challenges that HCV patients face, including those who are the most difficult to treat. Our pivotal HCV clinical trials for faldaprevir and deleobuvir are comprised of two multi-trial programs, STARTVerso® and HCVerso®.

Faldaprevir, also known as BI 201335, is an investigational, oral protease inhibitor that is specifically designed to target viral replication in the liver. Boehringer Ingelheim is developing faldaprevir as a core component of both interferon-based and interferon-free hepatitis C treatment regimens. STARTVerso®1 is the first of an ongoing multi-study Phase 3 trial program that is evaluating faldaprevir combined with PegIFN/RBV. Three additional trials in treatment-naive, treatment-experienced and HIV co-infected patients with chronic genotype-1 HCV are near clinical completion. Deleobuvir, also known as BI 207127, is an investigational NS5B non-nucleoside polymerase inhibitor that has shown the potential to eliminate interferon from HCV treatment when combined in a regimen with faldaprevir and RBV. Phase 2 trials of this interferon-free regimen have been completed and Phase 3 HCVerso® trials investigating this regimen are now underway. As part of our long-term commitment to HCV, the company is exploring other combinations o
'/>"/>

SOURCE Boehringer Ingelheim
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Boehringer Ingelheim Pharmaceuticals, Inc. Statement on RE-ALIGN Data
2. Boehringer Ingelheim Announces Agreement to Study Real-World Use of Oral Anticoagulants
3. Boehringer Ingelheim Renews and Expands License to NextBio Research Platform
4. Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company Statement on the ADA Request for Independent Review of Incretin-Based Therapies
5. Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference
6. Boehringer Ingelheim Presents Progression-Free Survival Data for Investigational Afatinib and Nintedanib in Advanced NSCLC
7. ASCO 2013: Boehringer Ingelheim to Present Data Across Multiple Cancers, Including Different Treatment Settings for Advanced NSCLC
8. Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company launch educational campaign about emerging science in type 2 diabetes
9. Boehringer Ingelheim to Announce Pivotal Phase 3 Hepatitis C Data at the International Liver Congress
10. European Medicines Agency accepts marketing authorization application for Boehringer Ingelheim and Eli Lilly and Companys empagliflozin*, an investigational type 2 diabetes treatment
11. Boehringer Ingelheim and Eli Lilly and Company submit new drug application to FDA for empagliflozin, an investigational type 2 diabetes treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... HILL, N.C. , Aug. 29, 2014 ... face of regulatory and marketplace changes. CI leaders who ... In a new Best Practices, LLC ... host of actionable insights, including: - Use ... cheaper than primary research - Internal staff ...
(Date:8/29/2014)...  A Boston Scientific Corporation (NYSE: ... and preliminary long term stricture resolution of benign ... issue of the peer-reviewed journal, Gastroenterology. ... conducted in 11 countries and five continents, and ... (FCSEMS) after extended indwell (i.e., up to 12 ...
(Date:8/29/2014)... Calif. , Aug. 29, 2014 Thoratec ... in device-based mechanical circulatory support therapies to save, support ... participating in the 2014 Morgan Stanley Global Healthcare Conference ... Burbach , President and Chief Executive Officer, will provide ... Eastern Daylight Time (9:55 a.m., Pacific Daylight Time).   ...
Breaking Medicine Technology:Using the Competitive Intelligence Function to Drive Better Business Decisions in the Pharmaceutical Sector 2Boston Scientific Study Published In Gastroenterology Reports Successful Management Of Benign Biliary Strictures With Fully Covered Metal Stents 2Boston Scientific Study Published In Gastroenterology Reports Successful Management Of Benign Biliary Strictures With Fully Covered Metal Stents 3Boston Scientific Study Published In Gastroenterology Reports Successful Management Of Benign Biliary Strictures With Fully Covered Metal Stents 4
... 26 BioMarin Pharmaceutical Inc. (Nasdaq: BMRN ... Pharmaceuticals, Inc. (Huxley), which has rights to a ... the rare autoimmune disease Lambert Eaton Myasthenic Syndrome ... Products for Human Use of the European Medicines ...
... PINNACLE Network (TM) Links Thousands of Clinical ... Excellence , WASHINGTON, Oct. 26 The ... of the PINNACLE Network(TM), the first-ever registry-based cardiovascular ... each other and to the ACC,s National Cardiovascular ...
Cached Medicine Technology:BioMarin Acquires Huxley Pharmaceuticals, Inc. 2BioMarin Acquires Huxley Pharmaceuticals, Inc. 3BioMarin Acquires Huxley Pharmaceuticals, Inc. 4BioMarin Acquires Huxley Pharmaceuticals, Inc. 5BioMarin Acquires Huxley Pharmaceuticals, Inc. 6American College of Cardiology Launches the Nation's First Registry-Based Cardiovascular Practice Network 2American College of Cardiology Launches the Nation's First Registry-Based Cardiovascular Practice Network 3
(Date:9/1/2014)... September 01, 2014 Currently, scientists ... effective treatments for Alzheimer's disease (AD), which reflects ... exist regarding the diagnosis of the disease, especially ... of appropriate diagnostic tests. In 2014, after ... greatest breakthroughs in the medicine world, there are ...
(Date:9/1/2014)... Los Angeles (PRWEB) September 01, 2014 ... fluctuations. These hormonal daily changes begin as early ... most of their lives negotiating the ups and downs ... skinny or thin or even healthy sizes seems to ... daily. As a woman in her 40's begin ...
(Date:9/1/2014)... Barcelona, Spain Monday 1 September 2014: Daily fruit ... up to 40%, according to research presented at ESC ... The findings from the seven year follow-up study of ... found that the more fruit people ate, the more ... "CVD, including ischaemic heart disease (IHD) and stroke, is ...
(Date:9/1/2014)... 2014 The National Association of Hispanic ... Dawn Bazarko, DNP, MPH, RN, and Adriana Perez, PhD, ... Academy of Nursing. They will be inducted with Immediate ... whose induction we reported last May. , Our three ... the 2014 American Academy of Nursing Policy Conference in ...
(Date:9/1/2014)... 01, 2014 In honor of National Take Your ... Animal Emergency & Referral Center of Minnesota (AERC) is offering a ... for their cats. , Many people don’t take their cat to ... a hassle,” but they wouldn’t decide not to take their kid ... cavity. The same goes for pets. Just like people want their ...
Breaking Medicine News(10 mins):Health News:Early Stage Minimally Invasive Candidate AD Biomarkers Reviewed in New Study by Biopharm Reports Available at MarketPublishers.com 2Health News:Early Stage Minimally Invasive Candidate AD Biomarkers Reviewed in New Study by Biopharm Reports Available at MarketPublishers.com 3Health News:Female Hormonal Imbalances - Can’t Seem to Shed Those Extra Pounds? Discussion with Medical Expert Dr. Clairborne on Dr. Carol Francis Talk Radio Today 2Health News:Female Hormonal Imbalances - Can’t Seem to Shed Those Extra Pounds? Discussion with Medical Expert Dr. Clairborne on Dr. Carol Francis Talk Radio Today 3Health News:Fruit consumption cuts CVD risk by up to 40 percent 2Health News:Fruit consumption cuts CVD risk by up to 40 percent 3Health News:Two Additional NAHN Members to be Inducted as Fellows of the American Academy of Nursing 2Health News:Two Additional NAHN Members to be Inducted as Fellows of the American Academy of Nursing 3Health News:Two Additional NAHN Members to be Inducted as Fellows of the American Academy of Nursing 4Health News:Animal Emergency & Referral Center of Minnesota Celebrates National Take Your Cat to the Vet Day 2Health News:Animal Emergency & Referral Center of Minnesota Celebrates National Take Your Cat to the Vet Day 3
... 14, 2012) A new study by University of ... for basal-like breast cancer, commonly known as triple-negative breast ... resistance to chemotherapy and occurs at women at a ... program that promotes cell migration and reduces adhesion between ...
... through colonoscopy is an effective treatment for recurrent ... study in Gastroenterology , the official journal of ... this study does not appear to be greater than ... itself seems to be a rather safe procedure. CDI ...
... large international study indicates that anti-inflammatory drugs may become ... disease (CHD), the leading global cause of death. In ... heart disease, the researchers used the Cardiochip, a gene ... researcher in the Center for Applied Genomics at The ...
... By Carina Storrs HealthDay Reporter , TUESDAY, March ... lot to do with factors like race, age and where ... patterns, according to a new study. Researchers analyzed food ... aged 45 and older in the continental United States, with ...
... Scientists have identified a new compound that rapidly kills ... liver cancer and fifth most common cancer worldwide, while ... (FQI1), works by inhibiting an oncogene originally discovered by ... Ph.D., Harrison Scholar at Virginia Commonwealth University (VCU) Massey ...
... 10 (HealthDay News) -- In people with a concussion, ... injury symptoms disappear, researchers have found. A test ... help improve treatment for people with a concussion, according ... led the study as a graduate student at the ...
Cached Medicine News:Health News:New study shows promise for developing new treatments for breast cancer 2Health News:A new treatment option for Clostridium difficile: Fecal transplantation 2Health News:Gene chip invented by CHOP scientist pinpoints new target to prevent heart disease 2Health News:Race, Location Big Factors in American Diets 2Health News:Race, Location Big Factors in American Diets 3Health News:New compound discovered that rapidly kills liver cancer 2Health News:'Delayed Reactions' May Outlast Other Concussion Effects 2
Toxoplasma IgG II ELISA...
ELISA kit for CMV CAP M....
Blunt tipped forceps with tungsten carbide treated jaws for enhanced gripping and removal of small sized foreign bodies....
Blunt tipped forceps with a thin tip angled at approximately 135 and hollowed out "notch" on the interior of the distal end. Tip is shaped like a pic when in the closed position. For membrane peeling...
Medicine Products: